Nasdaq, Dow, S&P 500 Futures Begin September On Weak Footing: Why NVDA, AAPL, TSLA, PANW, DELL, SLS, HUT Are In Focus
Retail sentiment on Stocktwits remained constructive despite rising geopolitical friction: ‘bullish’ on SPY and ‘neutral’ on QQQ.
Stocktwits
More News
SLS, IBRX Stocks Post August Gains: Eli Lilly’s Latest $2.9B Deal Has Retail Traders Bracing For An ‘M&A Rampage’
Retail traders viewed the Merida acquisition as evidence that Big Pharma will pay rich premiums for immune-focused platforms.
Stocktwits
Sellas CEO Stergiou Says ‘Rigorous, Unblinded’ Data From Pivotal AML Trial Will 'Speak For Itself' As REGAL Catalyst Nears
In a post on LinkedIn on Monday, Angelos Stergiou said despite speculation and outside commentary ‘naturally’ increasing, the company will let the data speak for itself.
Stocktwits
Why Are Nasdaq, S&P 500 Futures Subdued Premarket? NVDA, AAPL, INTC, CRWD, RKLB, SLS Stocks In Focus
Retail sentiment on Stocktwits remained constructive despite rising geopolitical friction: ‘bullish’ on SPY and ‘neutral’ on QQQ.
Stocktwits
Frank Gerola's BMF Targets SELLAS Life Sciences $3 Billion Valuation: Biotech's 'Most Expensive Coin Flip'
Short seller BMF Capital disclosed a short position in SELLAS Life Sciences, arguing the market has 'dangerously overvalued' the biotech.read more...
Benzinga
SLS Stock Rises Overnight: Healthcare Execs Tout AML Drug As ‘Game Changer’ Ahead Of Final Trial Trigger
An AstraZeneca sales executive called the Phase 3 Regal trial a “game changer” for AML patients in their first or second complete remission.
Stocktwits
How Are Nasdaq, Dow, S&P 500 Futures Reacting As US Launches Fresh Strike On Iran?
Geopolitics are back in the center stage over the weekend after the U.S. struck two Iranian rocket launchers late Sunday.
Stocktwits
When Revolution Medicines' FDA Win Lifts Other Boats: SELLAS Life Sciences Stock Surges
SELLAS stock gains momentum following FDA approval for Revolution Medicines, highlighting SLS009 preclinical pancreatic cancer data.read more...
ARK sees a path toward custom cancer treatments for every patient, though current costs of $200,000-$300,000 remain a major hurdle.
Stocktwits
Sellas Traders See Pancreatic Cancer Race After RVMD’s Drug Approval — But Near-Term Focus Remains On SLS’s Leukemia Pipeline
On Wednesday, the U.S. Food and Drug Administration approved RASONQUE, a once-daily pill for adults with metastatic pancreatic cancer who have already tried chemotherapy or cannot take multi-drug regimens.